Pluristem Therapeutics Inc. (PSTI)

4.14
NASDAQ : Health Technology
Prev Close 4.24
Day Low/High 4.14 / 4.30
52 Wk Low/High 3.24 / 13.50
Avg Volume 273.00K
Exchange NASDAQ
Shares Outstanding 15.55M
Market Cap 65.85M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sonus Networks, Novavax: Small-Cap Winner

Sonus Networks, Novavax: Small-Cap Winner

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Positive Pre-Clinical Data From Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication

Positive Pre-Clinical Data From Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication

Research Conducted at Berlin-Brandenburg Center for Regenerative Therapies and Charite University of Medicine Offers New Potentially Promising Cell Treatment for the Muscle Injury Market

Pluristem Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Pluristem Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

The Underwriters Have Exercised Over-Allotment Option in Full

AK Steel, Brinker: Small-Cap Winners

AK Steel, Brinker: Small-Cap Winners

TheStreet presents its rundown of winners in the small-cap space on Tuesday.

Sterling, Ener1: Small-Cap Winners

Sterling, Ener1: Small-Cap Winners

TheStreet presents its rundown of small-cap winners on Tuesday

ITT, AIG: Premarket Trading

ITT, AIG: Premarket Trading

Shares of ITT were surging after the company announced plans to split into three publicly traded companies.

Pluristem Therapeutics Approved For Dual Listing On The Tel Aviv Stock Exchange (TASE)

Pluristem Therapeutics Approved For Dual Listing On The Tel Aviv Stock Exchange (TASE)

In Addition to Trading on the NASDAQ, Pluristem's Shares of Common Stock to Begin Trading on TASE Under Ticker Symbol PLTR Starting December 19, 2010

Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock

Pluristem Therapeutics Inc. (Nasdaq: PSTI) (DAX: PJT) today announced that it has entered into definitive agreements with selected institutional and private investors to sell restricted common stock and warrants for...

Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today reported that data from clinical trials show the Company’s placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as...

Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that its PLX cell therapy product, derived from human placenta, a non-controversial, non-embryonic, adult stem cell source, was selected ...

Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain

Pluristem Therapeutics Inc. (Nasdaq: PSTI) (DAX: PJT) today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an ...

Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr.

Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that following its meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP), the...

Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that its off-the-shelf placenta-derived cell therapies will be the focus of presentations at upcoming investor and medical conferences.

Pluristem Therapeutics, Compugen: Early Volume Plays

Pluristem Therapeutics, Compugen: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Small-Cap Winners and Losers: ICT

Small-Cap Winners and Losers: ICT

The Newtown, Pa., company is being acquired by Aegis of India's Essar Group.

Monday's Health Winners & Losers

LifeCell surges on merger news.

M&A Trumps Election Anxiety

A flurry of mergers and acquistions gets the bulls juiced up Monday.

Bears Dazed and Confused by M&A

Deal-making in several sectors brings out the bulls ahead of an uncertain midterm election.

Monday's Health Winners & Losers

Adolor is plunging.

McKesson Buying Per-Se

It will pay $1.09 billion.

Today's Health Winners and Losers

Per-Se Technologies slides after a weaker-than-expected earnings report.

Tech Stocks Extend Charge

The Nasdaq has gained almost 60 points in two days. The S&P 500 hits a four-year high.

TheStreet Quant Rating: D- (Sell)